Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

104.51 +0.46 (+0.44%)
Official Closing Price Updated: 4:10 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
2 Healthcare Stocks to Buy Hand Over Fist in December
These stocks are great options now -- and most any month. 
Via The Motley Fool
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
These particular players look cheap right now. 
Via The Motley Fool
$1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Peering Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Spotlight on Abbott Laboratories: Analyzing the Surge in Options Activity
Via Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
1 Stock Down 15% This Year to Buy and Hold Forever
This stock has been delivering solid performances for a long time. 
Via The Motley Fool
2 No-Brainer Dividend Stocks to Buy This Week
These two top-income stocks are too cheap to ignore. 
Via The Motley Fool
Jim Cramer: Buy This Financial Stock, 'I Think They're High Quality'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vishay Intertechnology, Inc. 
Via Benzinga
Medtronic: oversold, overextended high yield reversal in play
The reversal in Medtronic has been brewing for some time but is gaining traction after strong second quarter earnings that came with improved guidance 
Via MarketBeat
Exposures COVID-19
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
New medicines for weight loss and diabetes stand to disrupt the competitive scene. 
Via The Motley Fool
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing
You'll be happy to own these top companies in any market environment. 
Via The Motley Fool
Novo Nordisk, Eli Lilly Skid — But These Weight-Loss Results Are 'Hard To Ignore'
Patients who took Wegovy for five years had a 70% reduced risk of developing diabetes. 
Via Investor's Business Daily
2 No-Brainer Stocks to Buy for Forever Dividend Growth
These companies generate billions of dollars in free cash flow every year. 
Via The Motley Fool
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
Investors could be making a mistake by selling off these stocks this year. 
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Dividend Kings to Buy for Royal Returns
Unlock the secrets of dividend kings, the aristocrats of the stock market with unparalleled records of raising dividends yearly. 
Via InvestorPlace
Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever
Dividend stocks can cushion your portfolio in times of market trouble. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Dividend Stocks That Are Investor Safe Havens
If there is such a thing as safe dividend stocks, these three should be at the top of your list to consider. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
SLB, Abbott And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by over 1% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
MedTech Giant DexCom Spotlight Is On G7 US Launch, Analyst Forecasts 22% Revenue Gain In 2024
Oppenheimer analyst Steven Lichtman reiterated the Outperform rating on DexCom, Inc. 
Via Benzinga
Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
The market has punished them, but don't overlook these stocks. 
Via The Motley Fool
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
Dividend aristocrats Caterpillar, NextEra, and Clorox have shown resilience in challenging times. These may offer opportunities as they are trading off highs. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories May Soon Launch a Game-Changing New Device in the U.S.
Abbott Laboratories is getting into the consumer wearables market. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
Exposures Economy
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.